Custom service
B Cell Sorting & Sequencing Platform
Native heavy–light chain pairing, recovered one cell at a time.
Hybridoma fusion recovers what the fusion event allows. Single B-cell sorting recovers what the immune system actually made. By depositing one antigen-specific B cell per well and amplifying its heavy and light chain transcripts from that same well, the native VH–VL pairing is preserved — no combinatorial pairing, no myeloma partner, no clone that only survives because it grows well in culture.
The platform is sample-agnostic. Splenocytes and lymph node cells from immunised mice or rabbits; PBMC from convalescent, vaccinated or naturally exposed donors; and sorted subsets such as plasmablasts, IgG-switched memory cells or IgA-secreting cells. Where the starting frequency is low — and in human samples it usually is — an antigen-tetramer enrichment step ahead of sorting is what decides whether a campaign returns five binders or fifty.
Sequencing depth is matched to the question. Sanger reads for tens of clones that will be expressed and tested; NGS when the interest is the repertoire itself, clonal lineage, somatic hypermutation load or CDR3 diversity. Both routes converge on the same expression and validation pipeline, so a sequence is never delivered without binding data behind it.
Service Highlights
Where it fits
The platform is usually chosen when the antibody itself is the deliverable rather than a screening tool: therapeutic lead discovery where the native pairing and mutation profile matter, anti-idiotype and anti-drug antibody reagents that need a defined paratope, and rare B cell subsets that would be lost in a fusion campaign. It is equally useful for reagents that a hybridoma cannot produce at all — rabbit monoclonals with a broad epitope footprint, or human antibodies from convalescent samples where no immunisation is possible.
It is a poor fit when the target is a difficult membrane protein with no soluble ectodomain to label, or when the budget only supports a polyclonal. We say so before the project starts, because a sorting campaign that cannot find specific cells is an expensive way to learn that.
Documentation and QC
Every campaign ships with a plate-level sort report, per-clone read counts, expression yield, SDS-PAGE or SEC-HPLC purity, and binding curves on the original antigen. Antibody sequences are supplied in FASTA and GenBank format alongside the expression constructs, so a clone can be re-expressed in your own laboratory without rebuilding it from a PDF.
Frequently asked questions
How many specific clones should we expect?
It depends almost entirely on the starting frequency. As a working figure, 1–5% of sorted antigen-positive cells yield a functional, well-expressing IgG; from a 2,880-well campaign we typically return 30–100 confirmed binders, and the enrichment step is what moves that number.
Can you work with frozen samples?
Yes. Cryopreserved PBMC or splenocytes are routine, provided viability on thaw is above 85%. Shipment on dry ice is preferable to fresh material for anything crossing a border, and we ask for roughly twice the cell number needed for a fresh sort.
Do we need to supply the antigen?
Not necessarily. If the antigen does not exist yet, peptide synthesis, recombinant expression and biotinylation are handled in house, which removes the two to three weeks usually lost in the hand-off. What we do need is a defined positive control, either a known antibody or a confirmed positive sample.
How is the sequence validated before delivery?
Each pair is checked for reading-frame integrity, expected CDR length and, where relevant, glycosylation sequons. Expression titre and monomer content are measured before the clone is accepted, so a sequence arriving in your inbox has already produced protein once.
Send the sample and, if you have it, the antigen. Before anything is committed, we will tell you whether the frequency in your sample justifies a sorting campaign — or whether a hybridoma or a display route will reach your antibody faster.
Service Highlights
- Index-sorted records for every well. Fluorophore combination, antigen staining intensity and light-chain gate are recorded per well, so any clone's selection can be audited afterwards.
- Paired VH/VL sequences. Amplified from the same well, so heavy and light chains are never recombined in vitro.
- Codon-optimised vectors. Human IgG1, mouse IgG2a, rabbit IgG, scFv or Fab, delivered as raw reads and as expression-ready constructs.
- Transient expression. In HEK293 or CHO with protein A or affinity purification; 0.1–1 mg of antibody is released per clone for functional work.
- Binding confirmed. By ELISA, BLI or SPR against the original antigen, with counter-screens, before any sequence is signed off.
- Species coverage. Mouse, rabbit, rat, human and NHP, including species where fusion efficiency is too low for a hybridoma campaign.
How the work runs
Sample review and assay design
We look at antigen quality, labelling strategy and available control samples first, then estimate the antigen-specific B cell frequency and set the plate count. A campaign sized on a guess wastes plates; a campaign sized on a titration does not.
Antigen-specific enrichment
Biotinylated antigen tetramers with streptavidin-conjugated magnetic beads, preceded by depletion of non-B cells. Frequency and viability are re-checked by flow before any cell is sorted, and the enriched fraction is documented in the report.
Single-cell sorting
Index sorting into 96- or 384-well PCR plates, one cell per well, lysis buffer pre-dispensed. Plates are sealed and frozen on dry ice immediately; the sort file links every well to its fluorescence profile.
RT-PCR and sequence recovery
VH and VL are amplified with framework-specific primer sets and nested PCR, then read by Sanger or NGS. Because heavy and light chain come from the same well, pairing is established by position rather than by inference.
Construct assembly and expression
Sequences are synthesised into the requested format, transfected into HEK293 or CHO, and cultured for 10–14 days. Purification is by protein A, protein G or antigen affinity, with endotoxin testing available.
Binding validation and reporting
Purified antibody is tested against the original antigen in the format you will use, with counter-screens for off-target binding. The report carries sequences, purity data, binding curves and the full sort record.
Specifications & timeline
- Timeline
- 4–6 weeks — from sample receipt
- Throughput
- 96–20,000 — single cells per campaign
- Output
- Paired VH/VL — + recombinant IgG
- Timeline
- 4–6 weeks from sample receipt: sorting and sequencing 2–3 weeks, expression and QC 2 weeks
- Sample input
- ≥1×10⁷ PBMC or ≥1×10⁶ splenocytes; fresh or cryopreserved (≥85% viability on thaw)
- Sorting throughput
- 96- and 384-well plates, up to 20 plates per campaign, index sorting available
- Sequencing
- Sanger for clone confirmation; NGS for repertoire, lineage and SHM analysis
- Expression hosts
- HEK293, CHO; E. coli for Fab and scFv fragments
- Deliverables
- Paired VH/VL sequences, expression plasmids, 0.1–1 mg purified antibody, binding data, sort report
- Species
- Mouse, rabbit, rat, human, NHP
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.